Addo, also known as thiopegfilgrastim injection, is recommended after high-intensity chemotherapy because it reduces the adverse effects of chemotherapy, decreases the probability of developing infections, and has multiple benefits for the organism, but it is not mandatory. Thiopegfilgrastim injection is a long-acting recombinant human granulocyte-stimulating factor, mainly for the prevention of post-chemotherapy neutropenia. The use of this drug after chemotherapy allows the granulocyte-stimulating factor to bind to hematopoietic cell surface receptors, stimulating the proliferation, differentiation, and maturation of hematopoietic cells and reducing the risk of chemotherapy adverse effects. Chemotherapeutic drugs may have the side effect of myelosuppression, leading to neutropenia and immune deficiency, as well as an increased risk of infections in the upper respiratory tract, lungs, skin, oral mucosa and urinary tract. To prevent and treat adverse reactions caused by chemotherapy, recombinant human granulocyte-stimulating factors, including thiopegfilgrastim injection, can be used, which is able to permanently stimulate the differentiation and maturation of bone marrow leukocytes and neutrophils, usually after 24 hours of chemotherapy. The short-acting recombinant human granulocyte-stimulating factor has a relatively short duration of action and does not play a prophylactic role. It can be temporarily injected daily when neutropenia occurs after chemotherapy and requires repeated blood tests. Therefore, it is generally recommended to use long-acting recombinant human granulocyte-stimulating factor such as thiopegfilgrastim injection after chemotherapy, which is convenient to operate and helps patients to reduce certain pain at the same time.